Supplementary Figure1-24 from Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic–Epigenetic Rewiring
Fig.S1. Analysis of the number of positive LNs and the lymph node ratio (LNR, the ratio of positive to examined nodes) in PDAC patients; Fig.S2. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S3. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S4. The senescence levels of PDAC patients with or without lymph node metastasis (LNM); Fig.S5. Validation of SPiDER probe and the effects of dasatinib plus quercetin; Fig.S6. The gating strategy for senescent cells and the senescence levels in normal tissues, IPMN and PDAC; Fig.S7. The effects of specific deletion of p16 and p21 in CAFs; Fig.S8.The effects of conditional deletion of p16 and p21 in CAFs; Fig.S9. Clinical significance of senescent CAFs in PDAC; Fig.S10. The paracrine effects of malignant epithelial components on the induction of senescent CAFs; Fig.S11. The validation of senescent CAFs; Fig.S12. The glucose metabolism level in senescent CAFs; Fig.S13. The effects of LDHA inhibition in LNM; Fig.S14. The effects of specific deletion of PHGDH in lymphatic endothelia cells. Data related to Fig.4P-R; Fig.S15. The evaluation of different lactylated histones in CAFs; Fig.S16. The distance between CAFs and Tregs in human and mouse models. Data related to Figure 6; Fig.S17. SenCAFs-derived lactate activates transcription of CCL17 by enhancing histone lactylation in LECs; Fig.S18. The HDAC inhibitor chidamide selectively kills senCAFs in PDAC; Fig.S19. The HDAC inhibitor chidamide selectively kills senCAFs, increases the efficacy of pancreatic cancer standard of care and further suppresses LNM and distal metastasis in PDAC;Fig.S20. The HDAC inhibitor chidamide could sensitize PDAC to chemoimmunotherapy;Fig.S21. The tumor re-challenge assay for chidamide plus chemoimmunotherapy; Fig.S22. The effects of chidamide in Pdgfrα-cre-p16/cdkn1aΔ and WT mice;Fig.S23. The therapeutic effects of gemcitabine, nab-paclitaxel, chidamide and QL1706 in PDX models;Fig.S24. Schematic illustration for the project.